Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas.
Recent reports indicate that the alterations in the p16 and pRb pathways can influence tumour progression and poor prognosis in several tumours. The objective of this study was to analyse p16 and pRb expression in161 patients with malignant fibrous histiocytomas (MFH). By immunohistochemistry, p16 and pRb were demonstrated in 25% and 56% of MFH, respectively. Cox regression analysis demonstrated an independent prognostic influence of both genes. Generally, the loss of p16 and pRb expression correlated with poorer prognosis. Promoter methylation of p16 was found in 16/42 of p16 negative MFH and of pRb in 2/42 of pRb-negative MFH. It can be concluded that p16 and pRb alterations play an important role in the progression of soft tissue sarcomas.
Brinck
Ulrich
U
Department of Pathology, Reinhard Nieter Hospital, Wilhelmshaven, Germany.
Schlott
Thilo
T
Störber
Steffi
S
Stachura
Jerzy
J
Bortkiewicz
Pawel
P
Nagel
Wolf-Dieter
WD
Hasse
Frank Michael
FM
Cordon-Cardo
Carlos
C
Fischer
Gösta
G
Korabiowska
Monika
M
D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism*; D019175:DNA Methylation; D051677:Histiocytoma, Malignant Fibrous / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D016160:Retinoblastoma Protein / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
D019941:Cyclin-Dependent Kinase Inhibitor p16; D016160:Retinoblastoma Protein